Literature DB >> 25735458

Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin.

Nathalie Coolen1, Philippe Morand2, Clémence Martin1, Dominique Hubert1, Reem Kanaan1, Jeanne Chapron1, Isabelle Honoré1, Daniel Dusser1, Etienne Audureau3, Nicolas Veziris4, Pierre-Régis Burgel5.   

Abstract

BACKGROUND: Azithromycin reduces exacerbations in cystic fibrosis (CF) patients. Our aim was to investigate its association with nontuberculous mycobacteria isolation and macrolide susceptibility.
METHODS: From 2006 to 2010, all adult CF subjects at Cochin Hospital (Paris, France) harboring at least one positive NTM isolate were identified (Cases). In a nested case-control study, each Case was individually matched for age and gender with up to 4 CF adults with no NTM isolate (Controls). Clinical data at the time of first NTM isolate (index date) in Cases were compared with those of Controls using multivariate conditional regression analysis.
RESULTS: CF subjects with positive NTM isolates (Cases, n=41) were matched to 155 Controls. Among Cases, 48.7% had isolates from Mycobacterium avium complex and 58.5% from Mycobacterium abscessus complex, and 31 Cases fulfilled the 2007 American Thoracic Society criteria for NTM infection (ATS+ Cases). Cases and ATS+ Cases were more likely to have low body mass index and colonization with Aspergillus fumigatus. Azithromycin was associated with a two-fold reduction in NTM isolates. Only one M. avium complex isolate had acquired macrolide resistance.
CONCLUSION: These data suggest that azithromycin is a primary prophylaxis for NTM infection in CF adults.
Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspergillus fumigatus; Cystic fibrosis; Macrolides; Nontuberculous mycobacteria; Risk factors

Mesh:

Substances:

Year:  2015        PMID: 25735458     DOI: 10.1016/j.jcf.2015.02.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  7 in total

Review 1.  [Evidence-based treatment of cystic fibrosis].

Authors:  F C Ringshausen; T Hellmuth; A-M Dittrich
Journal:  Internist (Berl)       Date:  2020-12       Impact factor: 0.743

Review 2.  Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications.

Authors:  Claire Edmondson; Jane C Davies
Journal:  Ther Adv Chronic Dis       Date:  2016-05-01       Impact factor: 5.091

3.  Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.

Authors:  Jonathan D Cogen; Frankline Onchiri; Julia Emerson; Ronald L Gibson; Lucas R Hoffman; David P Nichols; Margaret Rosenfeld
Journal:  Ann Am Thorac Soc       Date:  2018-06

Review 4.  Nontuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Kate Skolnik; Gordon Kirkpatrick; Bradley S Quon
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-22

5.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139

6.  CFTR Modulators Dampen Aspergillus-Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes.

Authors:  Alexander J Currie; Ellen T Main; Heather M Wilson; Darius Armstrong-James; Adilia Warris
Journal:  Front Cell Infect Microbiol       Date:  2020-07-24       Impact factor: 5.293

7.  Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey.

Authors:  Dirk Wagner; Jakko van Ingen; Roald van der Laan; Marko Obradovic
Journal:  BMJ Open Respir Res       Date:  2020-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.